Giovanni Luca Frassineti

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

Vito Lorusso, C. F. Pollera, Mauro Antimi et al. · European Journal of Cancer · 1998 · 289 citations

Surgical Oncology, Urology, Transitional Cell Carcinoma +8

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs

Francesco� Fabbri, Silvia Carloni, Wainer Zoli et al. · Cancer Letters · 2013 · 214 citations

Engineering, Cancer Detection, Medicine +10

Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life

Marco Maltoni, Emanuela Scarpi, Monia Dall’Agata et al. · European Journal of Cancer · 2016 · 182 citations · Full text

Nursing, Family Medicine, Palliative Care +8